Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis

Therapeutic Drug Monitoring

Volumn 24, Issue 3, 2002, Pages 338-345

  Lanchote, Vera L ^a   Garcia, Fab́iola S ^a   Dreossi, Sônia A C ^a   Takayanagui, Osvaldo Massaiti ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Albendazole; Antiepileptic drugs; Drug interactions; Neurocysticercosis; Pharmacokinetics

Indexed keywords

ALBENDAZOLE; ALBENDAZOLE SULFOXIDE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; DEXAMETHASONE; PHENOBARBITAL; PHENYTOIN; ANTHELMINTIC AGENT; DRUG DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; NEUROCYSTICERCOSIS; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG INTERACTION; FEMALE; ISOMERISM; MALE;

ADULT; ALBENDAZOLE; ANTHELMINTICS; ANTICONVULSANTS; AREA UNDER CURVE; CARBAMAZEPINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMAN; ISOMERISM; MALE; NEUROCYSTICERCOSIS; PHENOBARBITAL; PHENYTOIN; SUPPORT, NON-U.S. GOV'T; HUMANS;

EID: 0036001228     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200206000-00003     Document Type: Article

References (25)

1. Therapy for neurocysticercosis. Comparison between albendazole and praziquantel
2. Therapy for neurocysticercosis: A reappraisal
3. Albendazole therapy for neurocysticercosis: A prospective double-blind trial comparing 7 versus 14 days of treatment
4. Neurocysticercosis in the southeast of France, 1988-1998
5. Pharmacokinetics optimisation of the treatment of neurocysticercosis
6. Chemotherapy of cysticercosis
7. Pharmacokinetic interaction between praziquantel and albendazole in Sudanese men
8. Pharmacokinetics of albendazole in man
9. Albendazole treatment of echinococcosis in humans: Effects on microsomal metabolism and drug tolerance
10. Comparative enantioselectivity in the sulphoxidation of albendazole in man, dogs and rats
11. Chiral sulfoxidation of albendazole by the flavin adenine dinucleotide-containing and cytochrome P450-dependent mono-oxygenases from rat liver microsomes
12. Albendazole sulfonation by rat liver cytochrome P-450c
13. Relative contribution of cytochromes P-450 and flavin-containing mono-oxygenases to the metabolism of albendazole by human liver microsomes
14. Enantioselective kinetic disposition of albendazole sulfoxide in patients with neurocysticercosis
15. Dexamethasone increases plasma levels of albendazole
16. Therapy for neurocysticercosis: Pharmacokinetic interaction of albendazole sulfoxide with dexamethasone
17. Inhibition and induction of cytochrome P450 and the clinical implications
18. Pharmacokinetic interactions between antiepileptic drugs
19. Clinically significant pharmacokinetic drug interactions between antiepileptic drugs
20. Cytochrome P450 3A. Ontogeny and drug disposition
21. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2CI9
22. Simultaneous determination of albendazole sulfoxide enantiomers and albendazole sulfone in plasma
23. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation
24. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone